BioMarin Pharmaceutical Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.31B | $1.12B | $889.9M | $749.3M | $548.5M | $500.7M | $441.4M | $376.3M |
| Cost of Revenue | $241.8M | $209.6M | $152.0M | $122.3M | $88.4M | $91.8M | $84.0M | $70.3M |
| Gross Profit | $1.07B | $907.2M | $737.9M | $627.0M | $460.1M | $408.9M | $357.3M | $306.0M |
| Gross Margin | 81.6% | 81.2% | 82.9% | 83.7% | 83.9% | 81.7% | 81.0% | 81.3% |
| Operating Expenses | ||||||||
| Research & Development | $610.8M | $661.9M | $634.8M | $461.5M | $354.8M | $302.2M | $214.4M | $147.3M |
| SG&A Expense | $554.3M | $476.6M | $402.3M | $302.2M | $235.4M | $198.2M | $175.4M | $151.7M |
| Operating Income | $-14.7M | $-803.4M | $-110.7M | $-92.9M | $-156.0M | $-110.2M | $-33.9M | $544.0K |
| Operating Margin | -1.1% | -71.9% | -12.4% | -12.4% | -28.4% | -22.0% | -7.7% | 0.1% |
| Interest Expense | $42.7M | $39.5M | $38.2M | $36.6M | $10.4M | $7.6M | $8.4M | $10.8M |
| Pretax Income | $-35.9M | $-831.1M | $-154.7M | $-124.9M | $-176.5M | $-118.3M | $-43.6M | $-21.5M |
| Income Tax Expense | $81.2M | $-200.8M | $17.1M | $9.1M | $-150.0K | $-3.9M | $10.2M | $-227.3M |
| Net Income | $-117.0M | $-630.2M | $-171.8M | $-134.0M | $-176.4M | $-114.3M | $-53.8M | $205.8M |
| Net Margin | -8.9% | -56.4% | -19.3% | -17.9% | -32.2% | -22.8% | -12.2% | 54.7% |
| EPS (Basic) | $-0.67 | $-3.80 | $-1.07 | $-0.92 | $-1.28 | $-0.95 | $-0.48 | $2.00 |
| EPS (Diluted) | $-0.67 | $-3.81 | $-1.07 | $-0.92 | $-1.28 | $-0.95 | $-0.48 | $1.73 |
| Shares Outstanding (Basic) | 174.4M | 166.0M | 160.0M | 146.3M | 143.5M | 120.3M | 112.1M | 103.1M |
| Shares Outstanding (Diluted) | 174.4M | 166.2M | 160.0M | 146.3M | 143.5M | 120.3M | 112.1M | 125.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |